Navigation Links
Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
Date:3/13/2008

0820 for international callers; the conference ID number is 5074038. The replay will be available from 7:30 pm ET on Thursday, March 13 until 11:59 pm ET on Saturday, March 15. In addition the webcast will be archived for on-demand listening for 30 days at http://www.dendreon.com.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVE
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
7. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
8. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
9. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
10. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... SAN JOSE, California , January 15, 2014 ... antibody-drug conjugates for cancer, today announced the appointment of Thomas ... Reynolds has over 20 years, development experience gained in the ... Genetics. "I am delighted to welcome Tom at ...
(Date:1/15/2014)... More than 5 million Americans are currently living ... will die with Alzheimer’s or another dementia, according to ... many Americans into looking for ways to improve their ... cognitive disorders. Jonathan Weisman, president of Biohack Pure, is ...
(Date:1/15/2014)... 2014 2013 was a banner year ... Technologies®. They saw continued independent research led by the ... awarded a $1 million grant from the Susanne Marcus ... Behavior” a peer reviewed journal, Amy Grant highlighted Brainwave ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. – ... Warrington, Pa. , Details: The Hepatitis B Foundation, ... cure for hepatitis B and improving the quality of life ... on Friday, April 11 at Warrington Country Club in Warrington, ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
... 2011 Sangui enters commercialization phase / Initial ... State of Tamaulipas has issued an initial order of Hemo2Spray, ... wound debridement product Scabremove both registered by the Mexican authorities ... order of the wound spray and Sangui management is positive ...
... and myeloma are both malignant diseases that arise from ... lymph nodes and the bone marrow. Although considerable progress ... they remain a significant challenge for patients and their ... for lymphoma and myeloma will be presented today at ...
... Corp. (NASDAQ: BSTC ), a biopharmaceutical company ... ® in the U.S. and XIAPEX ® ... George Gould, Esq., to its Board of Directors effective ... of George M. Gould, LLC, and of counsel to ...
Cached Biology Technology:Mexican State of Tamaulipas Starts Training Doctors in Sangui Wound Management 2Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response 2Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response 3Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response 4Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response 5Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response 6Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response 7Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response 8Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response 9BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors 2BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors 3BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors 4
(Date:4/17/2014)... Luca Razzari of the nergie Matriaux Tlcommunications Research ... the John R. Evans Leaders Fund of the ... of state-of-the-art biotech and nanophotonics equipment. To this ... Ministre de l,Enseignement suprieur, de la Recherche, de ... new laboratories will help us develop new approaches ...
(Date:4/17/2014)... . Our eyes ... us with a continuous stream of information about our own ... in a car the world glides by us and ... effort, our brain calculates self-motion from this "optic flow". This ... gaze during our own movements. Together with biologists from the ...
(Date:4/17/2014)... Calif. One day about eight years ago, ... California, Riverside, and her father were on a field trip ... upon an orchid they had never seen before. , Unable ... on orchids. The orchid turned out to be an ... Lophiaris silverarum . , "Lophiaris" is the genus name, ...
Breaking Biology News(10 mins):New state-of-the-art biotech and nanotech equipment for INRS 2How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3
... than 200 million people worldwide and is a ... Osteoporosis Foundation. Resistance training often is recommended to ... (BMD), although previous studies that examined the effects ... Now, in a new study, University of Missouri ...
... cells tighten their belts: they start to digest their ... as autophagy - takes place in special organelles called ... have developed as a means of survival when times ... has become a kind of self-cleaning process. In mammalian ...
... team at the Centre for Stem Cell Research in Cambridge ... http://dev.biologists.org/ ) a new and safer way of generating pluripotent ... to every tissue of the body. Rapid developments in stem ... stem cell scientists to convert specialised cells, such as skin ...
Cached Biology News:Building strong bones: Running may provide more benefits than resistance training, MU study finds 2Self-digestion as a means of survival 2Researchers piggyback to safer reprogrammed stem cells 2
... The Jouan RC Maxi MB (for aqueous, ... vacuum concentrator/centrifugal evaporator systems respond to specific ... rapid and safe concentration of heat-labile samples. ... pumps, different of cold traps and a ...
... concentrator for efficient drying of small volumes ... system combines the SpeedVac™ Concentrator and chemically ... pump and rotor control, and dual timers ... time), makes the DNA120 indispensable in the ...
... Start up kit. Includes configured Laptop PC ... 1 MultiBlock satellite thermal Cycler (non-robotic). ... User friendly software. Store/track run data. ... lid. Outstanding uniformity. Advanced control ...
... Thermal Cycler is Thermo Electron's most advanced ... with easy to use sophisticated onboard software ... programming. Designed to offer performance, accuracy and ... a number of customer driven features built ...
Biology Products: